Shattuck Labs, Inc.
NASDAQ:STTK
Overview | Financials
| Company Name | Shattuck Labs, Inc. |
| Symbol | STTK |
| Currency | USD |
| Price | 1.88 |
| Market Cap | 90,058,016 |
| Dividend Yield | 0% |
| 52-week-range | 0.692 - 3.95 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Dr. Taylor H. Schreiber M.D., Ph.D. |
| Website | https://www.shattucklabs.com |
An error occurred while fetching data.
About Shattuck Labs, Inc.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD





